huSTEAP1 Mouse
Product Name
huSTEAP1 Mouse
Product ID
C002044
Strain Name
C57BL/6NCya-Steap1tm1(hSTEAP1)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “huSTEAP1 Mouse (Catalog C002044) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
STEAP1
Gene Alias
STEAP, PRSS24
NCBI ID
Chromosome
Chr 7 (Human)
MGI ID
Datasheet
Strain Description
STEAP1 (Six transmembrane epithelial antigen of the prostate 1) is a member of the six-transmembrane epithelial antigen family encoded by the STEAP1 gene and is primarily localized on the cell membrane surface. STEAP1 is highly expressed in multiple solid tumors, including prostate cancer, Ewing sarcoma, bladder cancer, and lung cancer, while its expression in normal tissues is relatively restricted [1-3]. STEAP1 is involved in biological processes including cell proliferation, redox homeostasis, and regulation of the tumor microenvironment, and has been associated with tumor invasion, metastasis, and poor prognosis in multiple malignancies [2-4]. Due to its tumor-associated high expression pattern and membrane localization, STEAP1 is considered an important target for cancer immunotherapy. Studies involving STEAP1-targeted monoclonal antibodies, antibody-drug conjugates (ADCs), T-cell engagers (TCEs), and CAR-T/CAR-NK cell therapies have been reported [3-5].
The huSTEAP1 mouse is a humanized model generated by replacing the sequence of exons 2 to 5 in the murine Steap1 gene with the corresponding sequence of human STEAP1 exons 2 to 5. This model is suitable for evaluating the in vivo efficacy and safety of STEAP1-targeted therapeutics, including monoclonal antibodies, ADCs, TCEs, and CAR-T/CAR-NK cells. Furthermore, it is applicable to research on the pathogenesis of prostate cancer and other STEAP1-overexpressing tumors, as well as studies on the tumor immune microenvironment and combination therapy strategies.
Reference
Gomes IM, Maia C J, Santos C R. STEAP proteins: from structure to applications in cancer therapy[J]. Molecular Cancer Research, 2012, 10(5): 573-587.
Ihlaseh-Catalano S M, Drigo S A, de Jesus C M N, et al. STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma[J]. Histopathology, 2013, 63(5): 678-685.
Yee N S, Zhang S, He H Z, et al. STEAP1: potential therapeutic target for prostate cancer and other cancers[J]. Pharmacology & Therapeutics, 2024, 254: 108517.
Kwon E D, Lee M J, Wang Y, et al. Targeting STEAP1 for cancer immunotherapy[J]. Nature Communications, 2023, 14(1): 2458.
Maia C J, Socorro S, Schmitt F, et al. STEAP1 is over-expressed in human prostate cancer and down-regulated by post-transcriptional mechanisms[J]. The Prostate, 2008, 68(13): 1426-1434.
Strain Strategy
The region from exon 2 to exon 5 of the mouse Steap1 was replaced with the region from exon 2 to exon 5 of the human STEAP1, with the humanized region encompassing both terminal UTRs.
Figure 1. Gene editing strategy of huSTEAP1 mice.
Application Area
Screening, development, and preclinical evaluation of STEAP1-targeted therapeutics;
Immunotherapy research for prostate cancer and other solid tumors;
Studies on the tumor immune microenvironment and combination therapy strategies.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
